Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 3, 2007, Pages 248-254

  Dunphy, Cherie Hilborn ^a,b   Nies, Melanie Kandt ^a   Gabriel, Don Alexander ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CD138; CD56; Cyclin D1; Plasma cell myeloma

Indexed keywords

CD56 ANTIGEN; CYCLIN D1; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL;

ANTIGENS, CD56; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MULTIPLE MYELOMA; PLASMA CELLS; SYNDECAN-1;

EID: 34548238805     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213136.93912.84     Document Type: Article

References (18)

1. Chilosi M, Adami F, Lestani M, et al. CD138/Syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12:1101-1106.
2. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001;68:269-275.
3. 2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplantation. 1999;23:1261-1266.
4. Rajkumar SV, Fonseca R, Lacy MQ, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999;17:1551-1557.
5. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160:1293-1299.
6. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56(NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977-1982.
7. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104:138-143.
8. Chang H, Bartlett E, Patterson B, et al. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol. 2005;129:539-541.
9. Hoechtlen-Vollmar W, Menzel G, Bartl R, et al. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol. 2000;109:30-38.
10. Athanasiou E, Kaloutsi V, Kotoula V, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol. 2001;116:535-542.
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
12. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
13. Mathew P, Ahmann GJ, Witzig TE, et al. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity? Br J Haematol. 1995;90:459-461.
14. Martin P, Santon A, Bellas C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology. 2004;44:375-380.
15. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885.
16. Rasmussen T, Knudsen LM, Johnson HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Euro J Haematol. 2001;67:296-301.
17. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102:1588-1594.
18. Cook JR, Hsi ED, Worley S, et al. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. AJCP. 2006;125:615-624.